Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,702.00-2.83%ETH$2,578.10-4.98%GOLD$4,143.70-1.04%OIL$90.08+0.72%
Smart Investors Daily
SID Premium
AM

NASDAQ · AMRX

Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$20.30

Down-$0.06 (-0.27%)

Updated Oct 7, 2026, 11:07 AM

SID Score

5.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.34B
P/E ratio
60.06
Dividend yield
0.00%
52-week range
$11.71 – $21.18
Volume
3.67M
Avg. volume
2.49M

Price performance · AMRX

AMRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

AMRX closed at $20.30 after 21 trading sessions, up 19.03% for the selected period.

Last close
$20.30
Period change
+19.03%
Period low
$16.65
Period high
$20.50
Daily close
View OHLC price history
AMRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$20.53$20.60$20.00$20.2953.67M
Oct 5, 2026$20.43$20.59$20.23$20.353.91M
Oct 2, 2026$20.19$20.54$19.995$20.302.82M
Oct 1, 2026$20.13$20.26$19.61$20.073.94M
Sep 30, 2026$20.29$20.4999$19.98$20.144.1M
Sep 29, 2026$20.43$20.78$20.06$20.202.85M
Sep 28, 2026$19.55$20.625$19.425$20.502.99M
Sep 25, 2026$20.00$20.00$19.3305$19.772.89M
Sep 24, 2026$19.29$19.86$19.19$19.8051.71M
Sep 23, 2026$19.70$20.17$18.735$19.333.58M
Sep 22, 2026$20.00$20.01$19.14$19.502.48M
Sep 21, 2026$18.96$21.175$18.775$20.165.91M
Sep 18, 2026$18.12$18.81$18.06$18.716.62M
Sep 17, 2026$18.56$19.18$18.12$18.282.82M
Sep 16, 2026$16.65$18.2999$16.56$18.085.12M
Sep 15, 2026$17.22$17.25$16.58$16.651.79M
Sep 14, 2026$17.11$17.30$16.98$17.221.6M
Sep 11, 2026$17.00$17.11$16.73$17.011.16M
Sep 10, 2026$17.22$17.3094$16.825$16.871.04M
Sep 9, 2026$17.27$17.36$17.08$17.251.47M
Sep 8, 2026$17.27$17.395$16.98$17.052.04M

Latest AMRX news

The latest Smart Investors Daily articles mentioning AMRX.

Stock researchCompany · Overview

AMRX research

Overview

Company profile and research snapshot.

Company profile

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
AMRX recent ratings
DateFirmRatingTarget
Sep 23, 2026OppenheimerOutperform—
Sep 17, 2026BarclaysOverweight—
Sep 9, 2026Leerink PartnersOutperform—
Aug 26, 2026JP MorganOverweight—
Aug 3, 2026UBSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 3, 2026

Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches

The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...

Yahoo · Sep 22, 2026

Why Is Amneal (AMRX) Stock Rocketing Higher Today

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 12.5% in the afternoon session after the company announced that the U.S. Food and Drug Administration approved its generic lanreotide injection for immediate launch.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By